An update on advances in the technologies available for translational research.  Sessions are to provide people with a better understanding of the talks they hear using the techniques described.  They also provide researchers with a guide to the techniques they should be considering for their studies.

Clinical Trials 102: New Strategies in Targetted Therapy Clinical Trials

Susan Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

and
Martine Piccart, MD, PhD
Jules Bordet Institute
Brussels, BELGIUM

RNAi and Target Discovery
Moderator:  C. Kent Osborne, MD, Baylor College of Medicine, Houston, TX

Conserved roles of small RNAs in genome defense

Gregory Hannon, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY

Technologies for Translational Research
Moderator:  Charles Perou, PhD, Lineberger Cancer Center, Chapel Hill, NC

Overview of Translational Technologies and Gene Expression Profiling

Charles Perou, PhD

Lineberger Cancer Center

Chapel Hill, NC

Sequencing of breast cancer genome

Michael Stratton, FRS

Institute of Cancer Research

Sutton, UNITED KINGDOM

Technological needs for realizing the opportunities offered by personalized medicine

Gordon Mills, MD, PhD

UT MD Anderson Cancer Center

Houston, TX

The Basics of Epigenetics, and its Biological and Clinical Relevance
Moderator:  Steffi Oesterreich, PhD, Baylor College of Medicine, Houston, TX

DNA methylation – Role in Gene Regulation, and methods to study it

Saraswati Sukumar, PhD

Johns Hopkins Oncology Center

Baltimore, MD

 

What is the Histone Code, and why is it important?

Steffi Oesterreich, PhD

Baylor College of Medicine

Houston, TX

 

Epigenetic Therapy – Past, Present, Future

Jean-Pierre Issa, MD

UT MD Anderson Cancer Center

Houston, TX

 

Breast Cancer Prevention
Moderator:  Powel Brown, MD, PhD, Baylor College of Medicine, Houston, TX

Judy Garber, MD

Dana-Farber Cancer Institute

Boston, MA

Advances in Preventive Therapy

Jack Cuzick, PhD

Wolfson Institute of Preventive Medicine

London, UNITED KINGDOM

AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen for the Cure®

TBA

AACR Distinguished Lectureship in Breast Cancer Research

Breast Cancer Stem Cells and the Epithelial-Mesenchymal Transition

Robert Weinberg, PhD
Whitehead Institute for Biomed

Cambridge, MA

William L. McGuire Memorial Lecture

International Breast Cancer Research : Launching an Expedition to the Moon  

Martine Piccart, MD, PhD

Jules Bordet Institute

Brussels, BELGIUM

An epidemiological perspective on the causes

Valerie Beral, MD

University of Oxford

Oxford, UNITED KINGDOM

Target the PI3K/AKT/mTOR pathway in cancer

William Sellers, MD

Novartis Institutes for Biomedical Research, Inc.
Cambridge, MA

New paradigms in tumor immunotherapy

Tyler Curiel, MD, MPH

UT Health Science Center

San Antonio, TX

Emerging use of nantotechnology in cancer diagnosis and therapy
Moderators: Jenny Chang, MD, Baylor College of Medicine, Houston, TX and Adrian Lee, PhD, Baylor College of Medicine, Houston, TX

Diagnostic and Therapeutic Applications of Nanotechnology

Jennifer West, PhD
Rice University
Houston, TX

Engineered polymeric nanoparticles for therapeutic and diagnostic application

Omid Farokhzad, MD

Harvard-MIT

Cambridge, MA

Host-related Factors in Breast Cancer
Moderator: Peter Ravdin, MD, UT Health Science Center, San Antonio, TX

Obesity, Insulin Resistance and Insulin

Pamela Goodwin, MD

Mount Sinai Hospital

Toronto, CANADA

Events in the bone micro-environment: Mechanisms of action of bisphonsphonates and other agents

Theresa Guise, MD

University of Virginia Health System

Charlottesville, VA

Local Control and Long-term Survival
Moderators: Jay Harris, MD, Dana-Farber Cancer Institute, Boston, MA and Monica Morrow, MD, FACS, Memorial Sloan-Kettering Cancer Center, New York, NY

Update on the EBCTCG's studies on the relationship between local treatment and long-term survival

Sarah Darby , PhD
CTSU Oxford University
Oxford, UNITED KINGDOM

How the ‘4:1 ratio’ will likely change with increasingly effective systemic therapy

Jay Harris, MD

Dana-Farber Cancer Institute

Boston, MA

Minimizing Local Recurrence:  What’s proven, what’s not

Monica Morrow, MD, FACS

Memorial Sloan-Kettering Cancer Center

New York, NY

Moderator:  C. Kent Osborne, MD, Baylor College of Medicine,

Houston, TX

Implications of Recent Advances in Basic Research
Adrian Lee, PhD
Baylor College of Medicine
Houston, TX

Translational Insights for Clinical Research and Practice
Carlos Arteaga, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN

Early Breast Cancer: 2009
Ian Smith, MD
Royal Marsden Hospital
London, UNITED KINGDOM

Metastatic Breast Cancer
Clifford Hudis, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Controversies in Breast Cancer Models for Drug Development
Moderator: Lewis Chodosh, MD, PhD, University of Pennsylvania, Philadelphia, PA

Our Inner Mouse: Genomic Insights From Mouse Mammary Cancer Models to Guide Pre-clinical Testing

Jeffrey E. Green, MD
NCI
Bethesda, MD

Pre-clinical models for development of marker guided therapy in breast cancer

Joe Gray, PhD

Lawrence Berkeley National Lab

Berkeley, CA

Is Extranuclear Estrogen Receptor (Ir)relevant?
Moderators: Suzanne Fuqua, PhD, Baylor College of Medicine, Houston, TX and Rachel Schiff, PhD, Baylor College of Medicine, Houston, TX

Extra-nuclear ERalpha and ERbeta signal to breast cancer cell biology

Ellis Levin, MD
UC Irvine Long Beach VA Hospital
Long Beach, CA

Membrane ER in endocrine resistance in the lab and the clinic: should we be convinced?

Mitchell Dowsett, MD, PhD

Royal Marsden Hospital NHS Trust

London, UNITED KINGDOM

Can We Measure Tumor Dormancy and Does It Matter?
Moderator: Tyler Curiel, MD, MPH, UT Health Science Center, San Antonio, TX

Cancer Immunoediting:  Immunologic Control and Sculpting of Cancer

Robert Schreiber, MD
Washington University School of Medicine
St. Louis, MO

TBA

Controversies in Adjuvant Chemotherapy
Moderator: James Ingle, MD, Mayo Clinic College of Medicine, Rochester, MN

Are there groups of patients who don't benefit from chemotherapy?

Peter Ravdin, MD, PhD

UT Health Science Center

San Antonio, TX

What are the best and most highly effective chemotherapy regimens?

Eric Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Moderator: Jenny Chang, MD, MB, Baylor College of Medicine, Houston, TX

Panelists:

TBA

Moderator: Jenny Chang, MD, MB, Baylor College of Medicine, Houston, TX

Panelists:

TBA

Bring your lunch and join roundtable discussions with senior scientists who are leaders in the field! This session is open to graduate students, medical students and residents, and clinical and postdoctoral fellows. Space is limited, and pre-registration is required. Return the registration form by November 24, 2009

.

Discussion topics may include grant writing, publication strategies, negotiating a job offer or promotion, oral presentation skills, setting up and managing a laboratory, working for or working with the pharmaceutical/biotech industry, how to get the most out of being a cooperative group member, the path to leading clinical trials, and balancing research and clinical practice.

12:00 PM-7:00 PM

3:30 PM-7:00 PM

7:00 AM-5:45 PM

8:30 AM-7:00 PM

11:00 AM-5:30 PM

6:45 AM-5:45 PM

7:00 AM-7:30 PM

11:00 AM-5:30 PM

6:45 AM-5:45 PM

7:00 AM-7:30 PM

11:00 AM-5:30 PM

6:45 AM-10:30 AM

7:00 AM-10:30 AM